Trial · NCT00943306
Outcomes54
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 54
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) | Baseline and Week 126 | Week 126 Completers Population | Percent Change | MEAN |
| SECONDARY | Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) | Baseline and Week 174 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) | Baseline and Week 222 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) | Baseline and Week 246 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) | Baseline and Week 270 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) | Baseline and Week 294 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Total Cholesterol | Baseline and Week 126 | Week 126 Completers Population | Percent Change | MEAN |
| SECONDARY | Percent Change in Total Cholesterol | Baseline and Week 174 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Total Cholesterol | Baseline and Week 222 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Total Cholesterol | Baseline and Week 246 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Total Cholesterol | Baseline and Week 270 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Total Cholesterol | Baseline and Week 294 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Apolipoprotein B (Apo B) | Baseline and Week 126 | Week 126 Completers Population | Percent Change | MEAN |
| SECONDARY | Percent Change in Apolipoprotein B (Apo B) | Baseline and Week 174 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Apolipoprotein B (Apo B) | Baseline and Week 222 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Apolipoprotein B (Apo B) | Baseline and Week 246 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Apolipoprotein B (Apo B) | Baseline and Week 270 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Apolipoprotein B (Apo B) | Baseline and Week 294 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
| SECONDARY | Percent Change in Triglycerides | Baseline and Week 126 | Week 126 Completers Population | Percent Change | MEAN |
| SECONDARY | Percent Change in Triglycerides | Baseline and Week 174 | Safety Population - The number of patients in the Safety Population at time points after Week 126 decreased because the study remained active within each country until either approval of the marketing application was obtained, or, in countries where marketing authorization was not sought for, patients transitioned into an Expanded Access Program. | Percent Change | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00943306/outcomes